Inspiring signals, IPF is expected to enter the era of inhalation therapy! ----RSN0402 Powder for I
Inspiring signals, IPF is expected to enter the era of inh...
Inspiring signals, IPF is expected to enter the era of inhalation therapy!----RSN0402 Powder for Inhalation developed by Resproly has successfully completed the enrollment of the ...
Dr. Chen Yongqi, the chairman of our company, attended the...
On June 17-18, 2021, the 'Improved New Drug Trend and Technology Conference' will be held at the Westin Hotel in Chongqing Jiefangbei. This summit is hosted by the Pharmaceutical I...
Dr. Hansen Luan was invited to serve as a member of the Scientific Advisory Committee of Zhuhai Resp
Dr. Hansen Luan was invited to serve as a member of the Sc...
On the afternoon of May 18, the appointment ceremony of Luan Hansen, a member of the Scientific Advisory Committee of Zhuhai Ruispuli Pharmaceutical Technology Co., Ltd., was held ...
Dr. Chen Yongqi, the chairman of our company, attended the...
With the introduction of foreign countries and the rise of domestic inhalation drug research and development, aerosol inhalation therapy has become one of the areas that have attra...
Dr. Chen Yongqi, Chairman of Resproly, shared the experience of inhalation preparation R&D and indus
Dr. Chen Yongqi, Chairman of Resproly, shared the experien...
On February 26, Dr. Chen Yongqi, Chairman and Chief Scientist of Resproly, participated in the high-level talent exchange meeting in Hengqin New Area. Starting from the recent Isra...
Resproly successfully held the 2020 commendation meeting
Resproly successfully held the 2020 commendation meeting
On February 3, Raspley held a simple and grand 2020 commendation conference. The conference was presided over by Deputy General Manager Dr. Huali. Chairman Chen Yongqi, Deputy Gene...